<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Argenx Se — News on 6ix</title>
<link>https://6ix.com/company/argenx-se</link>
<description>Latest news and press releases for Argenx Se on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 08 May 2026 21:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/argenx-se" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d68cd1beedb30cb6fef02b.webp</url>
<title>Argenx Se</title>
<link>https://6ix.com/company/argenx-se</link>
</image>
<item>
<title>argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-us-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use-in-all-adult-patients-living-with-gmg-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-us-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use-in-all-adult-patients-living-with-gmg-1</guid>
<pubDate>Fri, 08 May 2026 21:20:00 GMT</pubDate>
<description>VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegativePatients treated with VYVGART in the ADAPT SERON study experienced rapid, significant and sustained symptom improvements that continued with ongoing treatment Approval advances argenx’s commitment to address the unique needs of every MG patient, delivering the broadest MG label to d</description>
</item>
<item>
<title>argenx Reports First Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/argenx-se/news/argenx-reports-first-quarter-2026-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-reports-first-quarter-2026-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 07 May 2026 05:00:00 GMT</pubDate>
<description>$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative (“seronegative”) gMG PDUFA is May 10, 2026 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 7, 2026 7:00AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2026 results and provided a</description>
</item>
<item>
<title>argenx to Present at BofA Securities 2026 Health Care Conference</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-at-bofa-securities-2026-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-at-bofa-securities-2026-health-care-conference</guid>
<pubDate>Wed, 06 May 2026 20:30:00 GMT</pubDate>
<description>May 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcas</description>
</item>
<item>
<title>argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-results-of-annual-general-meeting-and-board-of-directors-appointment-of-karen-massey-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-results-of-annual-general-meeting-and-board-of-directors-appointment-of-karen-massey-as-chief-executive-officer</guid>
<pubDate>Wed, 06 May 2026 20:01:00 GMT</pubDate>
<description>Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. “Karen has earned the full co</description>
</item>
<item>
<title>argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-report-first-quarter-2026-financial-results-and-business-update-on-may-7-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-report-first-quarter-2026-financial-results-and-business-update-on-may-7-2026-1</guid>
<pubDate>Thu, 30 Apr 2026 05:00:00 GMT</pubDate>
<description>April 30, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com</description>
</item>
<item>
<title>argenx announces Annual General Meeting of Shareholders on May 6, 2026</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026-1</guid>
<pubDate>Fri, 20 Mar 2026 20:01:00 GMT</pubDate>
<description>March 20, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual Gen</description>
</item>
<item>
<title>Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics</title>
<link>https://6ix.com/company/argenx-se/news/unnatural-products-raises-dollar45-million-series-b-financing-to-advance-macrocyclic-peptide-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/unnatural-products-raises-dollar45-million-series-b-financing-to-advance-macrocyclic-peptide-therapeutics</guid>
<pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
<description>Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investorsSANTA CRUZ, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing led by The Venture Collective (TVC), with participation from argenx, Droia</description>
</item>
<item>
<title>argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-outcomes-in-mg-and-cidp-and-build-upon-strength-of-pipeline-10</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-outcomes-in-mg-and-cidp-and-build-upon-strength-of-pipeline-10</guid>
<pubDate>Fri, 06 Mar 2026 06:00:00 GMT</pubDate>
<description>Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART’s efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART’s expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (</description>
</item>
<item>
<title>argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update</title>
<link>https://6ix.com/company/argenx-se/news/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update-1</guid>
<pubDate>Thu, 26 Feb 2026 06:00:00 GMT</pubDate>
<description>$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Am</description>
</item>
<item>
<title>argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-ocular-myasthenia-gravis-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-ocular-myasthenia-gravis-1</guid>
<pubDate>Thu, 26 Feb 2026 05:30:00 GMT</pubDate>
<description>Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the</description>
</item>
<item>
<title>argenx to Present at TD Cowen 46th Annual Healthcare Conference</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference-1</guid>
<pubDate>Mon, 23 Feb 2026 06:00:00 GMT</pubDate>
<description>February 23, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors.</description>
</item>
<item>
<title>argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-february-26-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-february-26-2026-1</guid>
<pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
<description>February 19, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx w</description>
</item>
<item>
<title>argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priority-review-for-vyvgart-in-achr-ab-seronegative-gmg</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priority-review-for-vyvgart-in-achr-ab-seronegative-gmg</guid>
<pubDate>Tue, 13 Jan 2026 06:00:00 GMT</pubDate>
<description>January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalize</description>
</item>
<item>
<title>argenx Highlights 2026 Strategic Priorities</title>
<link>https://6ix.com/company/argenx-se/news/argenx-highlights-2026-strategic-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-highlights-2026-strategic-priorities</guid>
<pubDate>Mon, 12 Jan 2026 06:00:00 GMT</pubDate>
<description>Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; thre</description>
</item>
<item>
<title>argenx to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-at-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-at-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 06 Jan 2026 06:00:00 GMT</pubDate>
<description>January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl</description>
</item>
<item>
<title>argenx Announces Leadership Transition Marking Next Evolution of Growth</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-leadership-transition-marking-next-evolution-of-growth</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-leadership-transition-marking-next-evolution-of-growth</guid>
<pubDate>Mon, 05 Jan 2026 06:00:00 GMT</pubDate>
<description>Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and</description>
</item>
<item>
<title>argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease</title>
<link>https://6ix.com/company/argenx-se/news/argenx-provides-update-on-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-provides-update-on-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease</guid>
<pubDate>Mon, 15 Dec 2025 06:00:00 GMT</pubDate>
<description>15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Mo</description>
</item>
<item>
<title>argenx Announces Results of Extraordinary General Meeting of Shareholders</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders</guid>
<pubDate>Tue, 18 Nov 2025 21:01:00 GMT</pubDate>
<description>November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025. The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a 95.67% majorit</description>
</item>
<item>
<title>/C O R R E C T I O N from source -- argenx Canada Inc./</title>
<link>https://6ix.com/company/argenx-se/news/c-o-r-r-e-c-t-i-o-n-from-source-argenx-canada-inc</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/c-o-r-r-e-c-t-i-o-n-from-source-argenx-canada-inc</guid>
<pubDate>Wed, 05 Nov 2025 20:30:00 GMT</pubDate>
<description>argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC (efgartigimod alfa injection) as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP).</description>
</item>
<item>
<title>argenx Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/argenx-se/news/argenx-reports-third-quarter-2025-financial-results-and-provides-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-reports-third-quarter-2025-financial-results-and-provides-business-update-1</guid>
<pubDate>Thu, 30 Oct 2025 06:00:00 GMT</pubDate>
<description>$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to imp</description>
</item>
</channel>
</rss>